

# **Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Pipeline Review, H1 2018**

<https://marketpublishers.com/r/C5D7B148A2BEN.html>

Date: February 2018

Pages: 77

Price: US\$ 3,500.00 (Single User License)

ID: C5D7B148A2BEN

## **Abstracts**

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Pipeline Review, H1 2018

### **SUMMARY**

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Cancer/Testis Antigen 1 is a protein encoded by CTAG1A gene is an antigen that is over expressed in many cancers but that is also expressed in normal ovary and testis tissues which makes it a good candidate for a cancer vaccine.

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) pipeline Target constitutes close to 19 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 4, 8 and 5 respectively. Similarly, the universities portfolio in Phase I stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer, Fallopian Tube Cancer, Metastatic Melanoma, Soft Tissue Sarcoma, Glioblastoma Multiforme (GBM), Lung Cancer, Melanoma, Metastatic Ovarian Cancer, Ovarian Cancer, Synovial Sarcoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Astrocytoma,

Breast Cancer, Colorectal Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Gastric Cancer, Metastatic Breast Cancer, Myelodysplastic Syndrome, Peritoneal Cancer, Prostate Cancer, Sarcomas, Anaplastic Oligoastrocytoma, Bladder Cancer, Ewing Sarcoma, Head And Neck Cancer, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Kidney Cancer (Renal Cell Cancer), Metastatic Renal Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Myxoid Liposarcoma, Neuroblastoma, Oligodendroglioma, Osteosarcoma, Rhabdomyosarcoma, Round Cell Liposarcoma, Solid Tumor, Transitional Cell Cancer (Urothelial Cell Cancer) and Uterine Cancer.

The latest report Cancer/ Testis Antigen 1 - Pipeline Review, H1 2018, outlays comprehensive information on the Cancer/ Testis Antigen 1 (Autoimmunogenic Cancer/ Testis Antigen NY ESO 1 or Cancer/ Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cancer/ Testis Antigen 1 (Autoimmunogenic Cancer/ Testis Antigen NY ESO 1 or Cancer/ Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Cancer/ Testis Antigen 1 (Autoimmunogenic Cancer/ Testis Antigen NY ESO 1 or Cancer/ Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)

The report reviews Cancer/ Testis Antigen 1 (Autoimmunogenic Cancer/ Testis Antigen NY ESO 1 or Cancer/ Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics under development by companies and universities/research institutes based on information derived

from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics and enlists all their major and minor projects

The report assesses Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Overview

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Therapeutics Assessment

Assessment by Route of Administration

Assessment by Molecule Type

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Companies Involved in Therapeutics Development

Aduro BioTech Inc

Boehringer Ingelheim GmbH

Celldex Therapeutics Inc

GlaxoSmithKline Plc

Immune Design Corp

ImmunoFrontier Inc

Sanofi Pasteur SA

Scancell Holdings Plc

Vault Pharma Inc

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Drug Profiles

ADU-623 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BI-1361849 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CDX-1401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target CTAG1B for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology -  
Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CMB-305 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CMB-305 + G-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CUE-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CYN-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-305 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2241658A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMF-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMM-65 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LV-305 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCIB-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SV-283 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target NY-ESO-1, PRAME, MAGE-A3 and WT-1 for Acute Myeloid  
Leukemia and Myelodysplastic Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VCP-2292 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VPI-111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or  
Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) -  
Dormant Products

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or

*Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Anti...*

Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) -  
Product Development Milestones

Featured News & Press Releases

Oct 16, 2017: Immune Design Announces Positive FDA Feedback on Phase 3 Clinical  
Trial Design for CMB305 in Synovial Sarcoma Patients

Sep 08, 2017: New Randomized Data From CMB305 + Checkpoint Inhibitor Study  
Demonstrate Greater Clinical Benefit and Immune Response

Aug 30, 2017: Immune Design Announces New CMB305 + Checkpoint Inhibitor Topline  
Data from an Upcoming Presentation at the ESMO 2017 Congress

Jun 26, 2017: Scancell Holdings Announces SCIB-2 Patent Granted in Europe

Jun 05, 2017: Immune Design Updates Positive Data from Lead Cancer  
Immunotherapy Program CMB305 at ASCO Annual Meeting

Jun 01, 2017: Immune responses from early study of novel sarcoma vaccine

May 17, 2017: New Clinical and Biomarker Data Validate Immune Design's CMB305  
Program

Dec 05, 2016: Celldex Presents Data on CDX-1401 at the American Society of  
Hematology Annual Meeting

Oct 10, 2016: Scancell preparing SCIB2 for clinical study in lung cancer

Jun 08, 2016: Immune Design Announces Updated Results For Its Immuno-oncology  
Product Candidate LV305 at ASCO

Jun 08, 2016: Immune Design Announces Updated Results For Immuno-oncology  
Product Candidate CMB305 At ASCO

Jun 04, 2016: Celldex Therapeutics' CDX-1401, CDX-301 Combination Generates  
Potent NY-ESO-1 Immune Responses in Patients with Melanoma

Apr 21, 2016: Immune Design Announces Presentation on LV-305 at the 2016  
American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 18, 2016: Celldex Therapeutics Presents Poster on CDX-1401 at the AACR Annual  
Meeting 2016

Feb 09, 2016: Immune Design Announces Positive Topline Data From Phase 1 Clinical  
Trial of CMB305

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer



## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018  
Number of Products under Development by Therapy Areas, H1 2018  
Number of Products under Development by Indications, H1 2018  
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018  
Number of Products under Development by Companies, H1 2018  
Products under Development by Companies, H1 2018  
Products under Development by Companies, H1 2018 (Contd.1), H1 2018  
Products under Development by Companies, H1 2018 (Contd.2), H1 2018  
Products under Development by Companies, H1 2018 (Contd.3), H1 2018  
Number of Products under Investigation by Universities/Institutes, H1 2018  
Products under Investigation by Universities/Institutes, H1 2018  
Number of Products by Stage and Route of Administration, H1 2018  
Number of Products by Stage and Molecule Type, H1 2018  
Pipeline by Aduro BioTech Inc, H1 2018  
Pipeline by Boehringer Ingelheim GmbH, H1 2018  
Pipeline by Celldex Therapeutics Inc, H1 2018  
Pipeline by GlaxoSmithKline Plc, H1 2018  
Pipeline by Immune Design Corp, H1 2018  
Pipeline by ImmunoFrontier Inc, H1 2018  
Pipeline by Sanofi Pasteur SA, H1 2018  
Pipeline by Scancell Holdings Plc, H1 2018  
Pipeline by Vault Pharma Inc, H1 2018  
Dormant Products, H1 2018  
Dormant Products, H1 2018 (Contd.1), H1 2018  
Dormant Products, H1 2018 (Contd.2), H1 2018

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

### COMPANIES MENTIONED

Aduro BioTech Inc

Boehringer Ingelheim GmbH

Celldex Therapeutics Inc

GlaxoSmithKline Plc

Immune Design Corp

ImmunoFrontier Inc

Sanofi Pasteur SA

Scancell Holdings Plc

Vault Pharma Inc

## I would like to order

Product name: Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/C5D7B148A2BEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C5D7B148A2BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970